Not registered yet? Please contact our project manager Dr. Sara Stöber . This area is only for members of the research consortium.

Stay informed on the project!

27 February 2024

PANCAID’s second newsletter is out!

We’re thrilled to announce the release of PANCAID’s second newsletter! Dive into the latest updates and insights straight from the heart of our work.

Missed it? We got you! Simply read it online.

Want to stay informed on the project? Sign up to our newsletter here:

15 Janaury 2024

PANCAID: Second General Assembly Meeting

PANCAID’s second General Assembly Meeting took place at our partner CNIO from 17 to 19 January 2024. During the first half day, the consortium first witnessed a masterclass given by esteemed Francisco X. Real, MD, PhD, Senior Group Leader at CNIO and current chair of the CNIO Scientific Committee on “the topic of “Molecular pathophysiology of pancreatic ductal adenocarcinoma (PDAC)”. After this stellar lecture, PANCAID’s Early Career Scientists (ECS) each presented themselves as well as their work.

On the second day, after a warm welcome by the project coordinator Klaus Pantel, co-coordinator Matthias Löhr as well as CNIO members Núria Malats and Héctor Peinado, the meeting commenced with updates on the diverse work packages, plenum discussions and presentation of our Scientific and Ethical Advisory Board (SEAB) members.

The last day kicked off with a keynote lecture by Ellen Heitzer from our partner MUG on “Liquid biopsy in PDAC – Current status & implications for PANCAID”, followed by updates on the remaining work packages. The meeting was rounded off with valuable feedback from the SEABs and a final discussion led by the coordinators.

07 September 2023

PANCAID participates in first Annual Meeting of the EU Mission Cancer Cluster “Prevention and early detection (Screening)”

Organised an hosted by cluster member LUCIA in San Sebastián and remote, Matthias Löhr gave the introductory presentation of PANCAID.


PANCAID is an international research consortium aiming to develop a minimally invasive blood test using liquid biopsy to detect pancreatic cancer to facilitate early detection of the cancer and its precursors. With 16 partners + 1 associated partner from eight countries, the project has received funding for five years to potentially revolutionize current pancreatic cancer diagnosis methods and improve patient outcomes.

Learn More

Our vision

PANCAID strives to provide a minimally invasive blood test using a comprehensive panel of liquid biopsy diagnostics (LBx) for early detection of pancreatic cancer and its precursor lesions.

Read on

Why it matters

Pancreatic cancer is a malignant neoplasm that originates in the cells of the pancreas, an organ located in the abdominal cavity behind the stomach. It is known to be one of the most aggressive and deadly types of cancer, with a high mortality rate. Pancreatic cancer is often difficult to detect in its early stages, as it tends to show minimal or no symptoms until it reaches advanced stages. This makes it challenging to diagnose and treat, and contributes to its poor prognosis.

Discover more